{"id":3538,"date":"2026-01-19T12:59:18","date_gmt":"2026-01-19T11:59:18","guid":{"rendered":"https:\/\/fhucare.com\/?page_id=3538"},"modified":"2026-03-05T14:26:45","modified_gmt":"2026-03-05T13:26:45","slug":"citar","status":"publish","type":"page","link":"https:\/\/fhucare.com\/fr\/clinical-trials\/citar\/","title":{"rendered":"CITAR trial : Checkpoint Inhibitor Treatment of ARthritis"},"content":{"rendered":"\n<h2 class=\"wp-block-heading has-text-align-center\"><strong><mark style=\"background-color:rgba(0, 0, 0, 0)\" class=\"has-inline-color has-accent-2-color\">TOCILIZUMAB VS CORTICOSTEROIDS FOR RHEUMATOLOGIC-IRAE<\/mark><\/strong><\/h2>\n\n\n\n<p class=\"has-text-align-center\"><strong>A PHASE II RANDOMIZED OPEN LABEL STUDY<\/strong><\/p>\n\n\n\n<figure class=\"wp-block-table td-padding-top-0 td-padding-bottom-0\" style=\"margin-top:0;padding-top:0\"><table class=\"has-fixed-layout\" style=\"border-style:none;border-width:0px\"><tbody><tr><td><img loading=\"lazy\" decoding=\"async\" width=\"150\" height=\"70\" class=\"wp-image-3005\" style=\"width: 150px;\" src=\"https:\/\/fhucare.com\/wp-content\/uploads\/2026\/01\/Logo_CITAR.webp\" alt=\"\"><\/td><td><img loading=\"lazy\" decoding=\"async\" width=\"150\" height=\"75\" class=\"wp-image-4287\" style=\"width: 150px;\" src=\"https:\/\/fhucare.com\/wp-content\/uploads\/2026\/02\/karolinska-institut-150x75-1.png\" alt=\"\"><\/td><td><img loading=\"lazy\" decoding=\"async\" width=\"150\" height=\"50\" class=\"wp-image-2589\" style=\"width: 150px;\" src=\"https:\/\/fhucare.com\/wp-content\/uploads\/2025\/12\/logo_partenaire_AP-HP_80.webp\" alt=\"\"><\/td><td><img loading=\"lazy\" decoding=\"async\" width=\"150\" height=\"37\" class=\"wp-image-201\" style=\"width: 150px;\" src=\"https:\/\/fhucare.com\/wp-content\/uploads\/2025\/11\/Logo_FHU-Care2_2026_transparent.png\" alt=\"\"><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p>CITAR trial information :  <strong>Checkpoint Inhibitor Treatment of ARthritis<\/strong><\/p>\n\n\n\n<p><\/p>\n\n\n\n<p><strong>Title<\/strong> : CITAR &#8211; Comparison of the efficacy and safety of early use of IL-6R blockade with tocilizumab in combination with short-term glucocorticoids versus glucocorticoids alone for the treatment of arthritis induced by cancer immunotherapy by check point inhibitors: a randomized, open, multicentre, proof of concept, superiority, controlled clinical trial.<\/p>\n\n\n\n<div class=\"wp-block-buttons is-layout-flex wp-block-buttons-is-layout-flex\" style=\"padding-top:var(--wp--preset--spacing--30);padding-bottom:var(--wp--preset--spacing--30)\">\n<div class=\"wp-block-button\"><a class=\"wp-block-button__link wp-element-button\" href=\"https:\/\/euclinicaltrials.eu\/search-for-clinical-trials\/?lang=en&amp;EUCT=2022-501130-33-00\" style=\"padding-top:var(--wp--preset--spacing--30);padding-bottom:var(--wp--preset--spacing--30)\" target=\"_blank\" rel=\"noreferrer noopener\"><strong>EUCT number<\/strong> : 2022-501130-33-00<\/a><\/div>\n\n\n\n<div class=\"wp-block-button\"><a class=\"wp-block-button__link has-text-align-left wp-element-button\" style=\"padding-top:var(--wp--preset--spacing--30);padding-bottom:var(--wp--preset--spacing--30)\"><strong>Current nbr of patients enrolled:<\/strong><br><strong>Europe<\/strong>\ud83d\udfe9 <strong>25 <\/strong> <br><strong>France<\/strong> \ud83d\udfe6 <strong>4 <\/strong><\/a><\/div>\n\n\n\n<div class=\"wp-block-button\"><a class=\"wp-block-button__link wp-element-button\" style=\"padding-top:var(--wp--preset--spacing--30);padding-bottom:var(--wp--preset--spacing--30)\">\ud83d\udc49 <strong>Target: 112 patients \u2013 including 30 patients in France<\/strong><\/a><\/div>\n<\/div>\n\n\n\n<figure class=\"wp-block-image aligncenter size-full is-resized\"><img loading=\"lazy\" decoding=\"async\" width=\"1280\" height=\"720\" src=\"https:\/\/fhucare.com\/wp-content\/uploads\/2026\/03\/CITAR-poster_VF.jpg\" alt=\"\" class=\"wp-image-4656\" style=\"width:640px;height:auto\" srcset=\"https:\/\/fhucare.com\/wp-content\/uploads\/2026\/03\/CITAR-poster_VF.jpg 1280w, https:\/\/fhucare.com\/wp-content\/uploads\/2026\/03\/CITAR-poster_VF-500x281.jpg 500w, https:\/\/fhucare.com\/wp-content\/uploads\/2026\/03\/CITAR-poster_VF-768x432.jpg 768w\" sizes=\"auto, (max-width: 1280px) 100vw, 1280px\" \/><\/figure>\n\n\n\n<figure class=\"wp-block-image aligncenter size-full\"><a href=\"https:\/\/clinicaltrials.eu\/trial\/study-on-tocilizumab-and-prednisolone-for-arthritis-caused-by-cancer-immunotherapy-in-cancer-patients\/\" target=\"_blank\" rel=\" noreferrer noopener\"><img loading=\"lazy\" decoding=\"async\" width=\"640\" height=\"336\" src=\"https:\/\/fhucare.com\/wp-content\/uploads\/2026\/02\/CITAR_outreach.png\" alt=\"\" class=\"wp-image-4062\" srcset=\"https:\/\/fhucare.com\/wp-content\/uploads\/2026\/02\/CITAR_outreach.png 640w, https:\/\/fhucare.com\/wp-content\/uploads\/2026\/02\/CITAR_outreach-500x263.png 500w\" sizes=\"auto, (max-width: 640px) 100vw, 640px\" \/><\/a><\/figure>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>CITAR Flyer<\/strong>:&nbsp;<a href=\"https:\/\/fhucare.com\/wp-content\/uploads\/2026\/01\/CITAR_-_Tryptique_20250604_v1.pdf\" target=\"_blank\" rel=\"noreferrer noopener\">CITAR &#8211; Tryptique 2025 06 04 v1 [pdf]<\/a><\/li>\n\n\n\n<li><strong><mark style=\"background-color:rgba(0, 0, 0, 0)\" class=\"has-inline-color has-contrast-color\">Slides \u2013 Oncologist Staff M<\/mark>eeting, Gustave Roussy<\/strong>:&nbsp;&nbsp;<a href=\"https:\/\/fhucare.com\/wp-content\/uploads\/2026\/01\/CItar-prez_GR_sept_2025.pdf\" target=\"_blank\" rel=\"noreferrer noopener\">CItar-prez_GR_sept_2025.pdf<\/a><\/li>\n\n\n\n<li><strong>International Newsletter<\/strong>: <a href=\"https:\/\/fhucare.com\/wp-content\/uploads\/2026\/01\/CITAR_International_newsletter_20250923.pdf\" target=\"_blank\" rel=\"noreferrer noopener\">CITAR International newsletter 2025 09 23 [pdf]<\/a><\/li>\n\n\n\n<li><strong>Watch Dr. Samuel Bitoun\u2019s conference presentation of the <em>CITAR<\/em> study :<\/strong><\/li>\n<\/ul>\n\n\n\n<figure class=\"wp-block-image aligncenter size-full is-resized\" id=\"https:\/\/youtu.be\/LIQzdXq6eGc?si=vqNQ_76dnUgAUVN4&amp;t=1\"><a href=\"https:\/\/www.youtube.com\/embed\/LIQzdXq6eGc?si=sG7wx1ot1cAeDGX-&amp;start=1https:\/\/www.youtube.com\/embed\/LIQzdXq6eGc?si=sG7wx1ot1cAeDGX-&amp;start=1\" target=\"_blank\" rel=\" noreferrer noopener\"><img loading=\"lazy\" decoding=\"async\" width=\"832\" height=\"465\" src=\"https:\/\/fhucare.com\/wp-content\/uploads\/2026\/02\/image-1.png\" alt=\"\" class=\"wp-image-3894\" style=\"width:832px;height:auto\" srcset=\"https:\/\/fhucare.com\/wp-content\/uploads\/2026\/02\/image-1.png 832w, https:\/\/fhucare.com\/wp-content\/uploads\/2026\/02\/image-1-500x279.png 500w, https:\/\/fhucare.com\/wp-content\/uploads\/2026\/02\/image-1-768x429.png 768w\" sizes=\"auto, (max-width: 832px) 100vw, 832px\" \/><\/a><\/figure>\n\n\n\n<h3 class=\"wp-block-heading\"><\/h3>\n\n\n\n<p>Medical condition(s) : Patients with histologically (or via cytology) confirmed cancer that develop arthritis secondary to treatment with immune checkpoint inhibitors.<br>Trial Phase:&nbsp;Therapeutic exploratory (Phase II)<br>Transition trial : No<br>Sponsor : Karolinska University Hospital<br>Participants type : Patients<br>Age range : 65+ years, 18-64 years<br>Locations : Sweden, France<\/p>\n\n\n\n<p><br>Main objective :<em> <strong>Does early use of IL6R blockade with tocilizumab in combination with short-term glucocorticoids have a superior efficacy in controlling the arthritis (arm B) compared to GCs alone (arm A) (assessed as CDAI low disease activity or remission) at week 16?<\/strong><\/em><\/p>\n\n\n\n<p><\/p>\n\n\n\n<p><strong>More about CITAR Clinical Trial<\/strong>:<br><a href=\"https:\/\/euclinicaltrials.eu\/search-for-clinical-trials\/?lang=en&amp;EUCT=2022-501130-33-00\" target=\"_blank\" rel=\"noopener\">https:\/\/euclinicaltrials.eu\/search-for-clinical-trials\/?lang=en&amp;EUCT=2022-501130-33-00<\/a><\/p>\n\n\n\n<p><strong>Main contacts:<\/strong><\/p>\n\n\n\n<div class=\"wp-block-media-text is-stacked-on-mobile\" style=\"grid-template-columns:15% auto\"><figure class=\"wp-block-media-text__media\"><img loading=\"lazy\" decoding=\"async\" width=\"309\" height=\"360\" src=\"https:\/\/fhucare.com\/wp-content\/uploads\/2026\/01\/Katerine_Chatzidionysiou_Portrait.webp\" alt=\"\" class=\"wp-image-3563 size-full\"\/><\/figure><div class=\"wp-block-media-text__content\">\n<p>Sponsor <strong>Karolinska Institutet<\/strong> (KI) <br><strong>Dr Katerina CHATZIDIONYSIOU<\/strong><br><em>Senior consultant Rheumatologist.<\/em><br>Head of the Clinical Trial Department Rheumatology Unit, Karolinska University Hospital<br>Email&nbsp;: <a href=\"mailto:aikaterini.chatzidionysiou@ki.se\"><\/a><a href=\"mailto:aikaterini.chatzidionysiou@ki.se\">aikaterini.chatzidionysiou@ki.se<\/a><\/p>\n<\/div><\/div>\n\n\n\n<div class=\"wp-block-media-text is-stacked-on-mobile is-vertically-aligned-center\" style=\"grid-template-columns:15% auto\"><figure class=\"wp-block-media-text__media\"><img loading=\"lazy\" decoding=\"async\" width=\"270\" height=\"270\" src=\"https:\/\/fhucare.com\/wp-content\/uploads\/2026\/02\/Dr_Samuel-Bitoun_portrait_carre.jpg\" alt=\"\" class=\"wp-image-4292 size-full\" srcset=\"https:\/\/fhucare.com\/wp-content\/uploads\/2026\/02\/Dr_Samuel-Bitoun_portrait_carre.jpg 270w, https:\/\/fhucare.com\/wp-content\/uploads\/2026\/02\/Dr_Samuel-Bitoun_portrait_carre-150x150.jpg 150w\" sizes=\"auto, (max-width: 270px) 100vw, 270px\" \/><\/figure><div class=\"wp-block-media-text__content\">\n<p>Sponsor <strong>AP-HP<\/strong> (project code : APHP 240143)<br><strong>Dr Samuel BITOUN<\/strong><br><em>Coordinating investigator<\/em><br>Immunology and rheumatology department at Bic\u00eatre Hospital<br>E-mail: <a href=\"mailto:samuel.bitoun@aphp.fr\">samuel.bitoun@aphp.fr<\/a><br>Phone: <a href=\"tel:33145217287\">+33(0)1.45.21.72.87<\/a><\/p>\n<\/div><\/div>\n\n\n\n<div class=\"wp-block-media-text is-stacked-on-mobile\" style=\"grid-template-columns:15% auto\"><figure class=\"wp-block-media-text__media\"><img loading=\"lazy\" decoding=\"async\" width=\"1024\" height=\"1024\" src=\"https:\/\/fhucare.com\/wp-content\/uploads\/2026\/01\/Clea_Bardon_Portrait_square-1024x1024.webp\" alt=\"\" class=\"wp-image-3564 size-full\" srcset=\"https:\/\/fhucare.com\/wp-content\/uploads\/2026\/01\/Clea_Bardon_Portrait_square-1024x1024.webp 1024w, https:\/\/fhucare.com\/wp-content\/uploads\/2026\/01\/Clea_Bardon_Portrait_square-500x500.webp 500w, https:\/\/fhucare.com\/wp-content\/uploads\/2026\/01\/Clea_Bardon_Portrait_square-150x150.webp 150w, https:\/\/fhucare.com\/wp-content\/uploads\/2026\/01\/Clea_Bardon_Portrait_square-768x768.webp 768w, https:\/\/fhucare.com\/wp-content\/uploads\/2026\/01\/Clea_Bardon_Portrait_square.webp 1026w\" sizes=\"auto, (max-width: 1024px) 100vw, 1024px\" \/><\/figure><div class=\"wp-block-media-text__content\">\n<p><strong>Dr Clea BARDON<\/strong><br><strong>Institut Gustave Roussy<\/strong><br>Email: <a href=\"mailto:clea.bardon@aphp.fr\">clea.bardon@aphp.fr<\/a><br>Phone: <a href=\"tel:330145222522\">+33(0)1.45.22.25.22<\/a><\/p>\n<\/div><\/div>\n\n\n\n<div style=\"height:24px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<div class=\"wp-block-group is-style-plain is-layout-flow wp-block-group-is-layout-flow\">\n<h2 class=\"wp-block-heading\"><strong>French Centers<\/strong> (<strong>30 <\/strong>patients in France) :<strong> <\/strong><\/h2>\n\n\n\n<h3 class=\"wp-block-heading\"><strong><mark style=\"background-color:rgba(0, 0, 0, 0)\" class=\"has-inline-color has-accent-4-color\">Bic\u00eatre AP-HP<\/mark><\/strong><\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Samuel Bitoun<\/strong> <br>Department of Immunology and Rheumatology, Bic\u00eatre Hospital, Le Kremlin-Bic\u00eatre, France<\/li>\n\n\n\n<li><strong>Olivier Lambotte<\/strong> <br>Department of Internal Medicine and Clinical Immunology, Universit\u00e9 Paris-Saclay, Bic\u00eatre Hospital, Le Kremlin-Bic\u00eatre, France<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\"><strong><mark style=\"background-color:rgba(0, 0, 0, 0)\" class=\"has-inline-color has-accent-4-color\">Brest<\/mark><\/strong><\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Divi Cornec<\/strong> <br>INSERM UMR1227 \u2013 B Lymphocytes, Autoimmunity and Immunotherapies Universit\u00e9 de Bretagne Occidentale Department of Rheumatology, CHRU Brest, Brest, France<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\"><strong><mark style=\"background-color:rgba(0, 0, 0, 0)\" class=\"has-inline-color has-accent-4-color\">Bordeaux<\/mark><\/strong><\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Christophe Richez<\/strong> <br>Department of Rheumatology, Bordeaux University Hospital, Bordeaux, France<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\"><strong><mark style=\"background-color:rgba(0, 0, 0, 0)\" class=\"has-inline-color has-accent-4-color\">Strasbourg<\/mark><\/strong><\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Jacques-Eric Gottenberg<\/strong> <br>Department of Rheumatology, CHRU Strasbourg, Strasbourg, France<\/li>\n<\/ul>\n<\/div>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>Study methodology:<\/strong><\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Phase II trial<\/li>\n\n\n\n<li>Randomised<\/li>\n\n\n\n<li>Controlled<\/li>\n\n\n\n<li>Open-label<\/li>\n\n\n\n<li>Multicentre<\/li>\n\n\n\n<li>Rheumatology units&nbsp;<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>Study population and number of patients:<\/strong><\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Patients treated with <strong>immune checkpoint inhibitors<\/strong> (ICIs) for <strong>cancer<\/strong> who develop <strong>inflammatory arthritis<\/strong> induced by these <strong>ICIs<\/strong>.<\/li>\n\n\n\n<li><strong>112<\/strong> patients (<strong>56<\/strong> in each group)<\/li>\n\n\n\n<li>Including <strong>30<\/strong> in France: Bic\u00eatre, Bordeaux, Brest, Strasbourg.<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>Primary objective :<\/strong><\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Evaluation of the effect of early use of <strong>tocilizumab<\/strong> in combination with <strong>glucocorticoids<\/strong> (15 days) (arm B)<\/li>\n\n\n\n<li>VS<\/li>\n\n\n\n<li><strong>Glucocorticoids alone<\/strong> (arm A) on the CDAI at week 16.<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>Treatment in the study :&nbsp;<\/strong><\/h3>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><tbody><tr><td class=\"has-text-align-center\" data-align=\"center\">Arm A :&nbsp;<br><strong>Prednisolone<\/strong><\/td><td class=\"has-text-align-center\" data-align=\"center\">Arm B :&nbsp;<br><strong>Tocilizumab + Prednisolone reduction<\/strong><\/td><\/tr><tr><td class=\"has-text-align-center\" data-align=\"center\"><img loading=\"lazy\" decoding=\"async\" width=\"300\" height=\"161\" class=\"wp-image-3559\" style=\"width: 300px;\" src=\"https:\/\/fhucare.com\/wp-content\/uploads\/2026\/01\/Treatment_in_the_study_001.jpg\" alt=\"\"><\/td><td class=\"has-text-align-center\" data-align=\"center\"><img loading=\"lazy\" decoding=\"async\" width=\"300\" height=\"232\" class=\"wp-image-3546\" style=\"width: 300px;\" src=\"https:\/\/fhucare.com\/wp-content\/uploads\/2026\/01\/002.jpg\" alt=\"\"><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>Inclusion criteria :&nbsp;<\/strong><\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Patients with histologically (or cytologically) confirmed cancer who develop arthritis (diagnosed by a rheumatologist) secondary to treatment with immune checkpoint inhibitors*<br>*Patients may be on monotherapy with ICIs or on combination therapy with two ICIs (e.g., ipilimumab and nivolumab). Patients may be receiving ICI in combination with chemotherapy<\/li>\n\n\n\n<li>At least 2 joints involved (clinically defined) + CDAI &gt; 10<\/li>\n\n\n\n<li>Performance status (ECOG\/WHO) 0-1; performance status 2 due to ongoing irAEs is permitted<\/li>\n\n\n\n<li>Patients already receiving glucocorticoids, regardless of dose, for the treatment of arthritis may be included if the duration of glucocorticoid treatment does not exceed 1 week<\/li>\n\n\n\n<li>Women of childbearing potential must have a negative pregnancy test (blood or urine) at enrolment<\/li>\n\n\n\n<li>Women must be post-menopausal for at least 1 year or be willing and able to use highly effective contraception during treatment and for up to 3 months after the last dose of the study drug<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>Exclusion criteria :<\/strong><\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Mild arthritis requiring no treatment other than NSAIDs or analgesics<\/li>\n\n\n\n<li>Presence of a life-threatening or organ-threatening treatment-related adverse event (irAE) requiring high doses of glucocorticoids<\/li>\n\n\n\n<li>Current treatment with glucocorticoids for other indications that cannot be discontinued<\/li>\n\n\n\n<li>History of inflammatory rheumatic disease prior to cancer diagnosis<\/li>\n\n\n\n<li>Current participation or participation in an investigational agent study or use of an investigational device within 4 weeks prior to the first dose of treatment<\/li>\n\n\n\n<li>Diagnosis of immunodeficiency or ongoing systemic immunosuppressive therapy, other than steroids, prior to the first dose of study treatment<\/li>\n\n\n\n<li>Treatment with a non-biological immunosuppressive or immune system modulating drug<\/li>\n\n\n\n<li>Treatment with other biological immune system modulating agents (other than ICIs) within 4 weeks prior to the start of treatment<\/li>\n\n\n\n<li>Vaccination with a live vaccine within 4 weeks prior to the first dose of the study drug or anticipated need for live vaccination during the study, including at least 30 days after the last dose of the study drug<\/li>\n\n\n\n<li>History of anaphylaxis or immunoglobulin E-mediated hypersensitivity to murine proteins or any component of tocilizumab. History of allergic reactions attributed to compounds with a chemical or biological composition similar to that of tocilizumab.<\/li>\n\n\n\n<li>History of hypersensitivity to prednisolone or any of its excipients.<\/li>\n\n\n\n<li>History of HIV or other immunodeficiencies<\/li>\n\n\n\n<li>History or current evidence of any condition, therapy, or laboratory abnormality that could distort the results of the trial, interfere with the subject&rsquo;s participation throughout the trial, or that would not be in the subject&rsquo;s best interest to participate, in the opinion of the treating investigator<\/li>\n\n\n\n<li>History of psychiatric disorders or substance abuse that would interfere with cooperation with trial requirements<\/li>\n\n\n\n<li>History of chronic viral hepatitis, alcoholic or metabolic liver disease<\/li>\n\n\n\n<li>Central nervous system (CNS) metastases<\/li>\n\n\n\n<li>History of or current positive purified protein derivative (PPD) tuberculin test<\/li>\n\n\n\n<li>Transplanted organs<\/li>\n\n\n\n<li>Active infection<\/li>\n\n\n\n<li>Pregnancy or breastfeeding<\/li>\n\n\n\n<li>Demyelinating disorders of the central nervous system or pre-existing seizure disorders<\/li>\n\n\n\n<li>History of diverticulitis, diverticulosis requiring antibiotic treatment, or other symptomatic gastrointestinal (GI) conditions that may promote perforation<\/li>\n\n\n\n<li>Adequate organ and bone marrow function<\/li>\n\n\n\n<li>Aspartate aminotransferase (AST) (SGOT)\/alanine aminotransferase (ALT) (SGPT) \u22642 \u00d7 institutional upper limit of normal<\/li>\n\n\n\n<li>Creatinine clearance Creatinine clearance \u226530 mL\/min<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>Design &amp; Procedure :<\/strong><\/h3>\n\n\n\n<figure class=\"wp-block-image size-full\"><img loading=\"lazy\" decoding=\"async\" width=\"1280\" height=\"720\" src=\"https:\/\/fhucare.com\/wp-content\/uploads\/2026\/02\/CItar-design.jpg\" alt=\"\" class=\"wp-image-4563\" srcset=\"https:\/\/fhucare.com\/wp-content\/uploads\/2026\/02\/CItar-design.jpg 1280w, https:\/\/fhucare.com\/wp-content\/uploads\/2026\/02\/CItar-design-500x281.jpg 500w, https:\/\/fhucare.com\/wp-content\/uploads\/2026\/02\/CItar-design-768x432.jpg 768w\" sizes=\"auto, (max-width: 1280px) 100vw, 1280px\" \/><\/figure>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>Others contacts <\/strong>:<\/h3>\n\n\n\n<div class=\"wp-block-columns is-layout-flex wp-container-core-columns-is-layout-28f84493 wp-block-columns-is-layout-flex\">\n<div class=\"wp-block-column is-layout-flow wp-block-column-is-layout-flow\" style=\"flex-basis:290px\">\n<div class=\"wp-block-group has-global-padding is-layout-constrained wp-block-group-is-layout-constrained\">\n<p>Main AP-HP contact DRCI<br><strong><a href=\"charline.menanteau@aphp.fr\" target=\"_blank\" rel=\"noreferrer noopener\">Charline MENANTEAU<\/a><\/strong><\/p>\n\n\n\n<div style=\"height:25px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p>Phone :<br><a href=\"tel:330140274178\">+33(0)1 40 27 41 78<\/a><\/p>\n<\/div>\n<\/div>\n\n\n\n<div class=\"wp-block-column is-layout-flow wp-block-column-is-layout-flow\" style=\"flex-basis:290px\">\n<div class=\"wp-block-group has-global-padding is-layout-constrained wp-block-group-is-layout-constrained\">\n<p>R\u00e9f\u00e9rente DRCI-URC<br><strong><a href=\"Ikrame.ramdhani@aphp.fr\" target=\"_blank\" rel=\"noreferrer noopener\">Ikrame RAMDHANI<\/a><\/strong><\/p>\n\n\n\n<p>URC Paris Sud, Bic\u00eatre<\/p>\n\n\n\n<p>Phone : <br><a href=\"tel:33145212180\">+33(0)1 45 21 21 80<\/a><\/p>\n<\/div>\n<\/div>\n\n\n\n<div class=\"wp-block-column is-layout-flow wp-block-column-is-layout-flow\" style=\"flex-basis:290px\">\n<div class=\"wp-block-group has-global-padding is-layout-constrained wp-block-group-is-layout-constrained\">\n<p>Attach\u00e9e recherche clinique&nbsp;<br><strong><a href=\"chanez.haddadou@aphp.fr\" target=\"_blank\" rel=\"noreferrer noopener\">Chanez HADDADOU<\/a><\/strong><\/p>\n\n\n\n<p>URC Paris Sud, Bic\u00eatre<\/p>\n\n\n\n<p>Phone :<br>+33(0)1 45 21 63 23 <\/p>\n<\/div>\n<\/div>\n<\/div>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\" style=\"border-style:none;border-width:0px\"><tbody><tr><td><img loading=\"lazy\" decoding=\"async\" width=\"150\" height=\"70\" class=\"wp-image-3005\" style=\"width: 150px;\" src=\"https:\/\/fhucare.com\/wp-content\/uploads\/2026\/01\/Logo_CITAR.webp\" alt=\"\"><\/td><td><img loading=\"lazy\" decoding=\"async\" width=\"150\" height=\"150\" class=\"wp-image-2888\" style=\"width: 150px;\" src=\"https:\/\/fhucare.com\/wp-content\/uploads\/2026\/01\/karolinska-institut.png\" alt=\"\" srcset=\"https:\/\/fhucare.com\/wp-content\/uploads\/2026\/01\/karolinska-institut.png 300w, https:\/\/fhucare.com\/wp-content\/uploads\/2026\/01\/karolinska-institut-150x150.png 150w\" sizes=\"auto, (max-width: 150px) 100vw, 150px\" \/><\/td><td><img loading=\"lazy\" decoding=\"async\" width=\"150\" height=\"150\" class=\"wp-image-2961\" style=\"width: 150px;\" src=\"https:\/\/fhucare.com\/wp-content\/uploads\/2026\/01\/logo_AP-HP_300-1.png\" alt=\"\" srcset=\"https:\/\/fhucare.com\/wp-content\/uploads\/2026\/01\/logo_AP-HP_300-1.png 300w, https:\/\/fhucare.com\/wp-content\/uploads\/2026\/01\/logo_AP-HP_300-1-150x150.png 150w\" sizes=\"auto, (max-width: 150px) 100vw, 150px\" \/><\/td><td>&nbsp;<img loading=\"lazy\" decoding=\"async\" width=\"150\" height=\"37\" class=\"wp-image-201\" style=\"width: 150px;\" src=\"https:\/\/fhucare.com\/wp-content\/uploads\/2025\/11\/Logo_FHU-Care2_2026_transparent.png\" alt=\"\"><\/td><\/tr><\/tbody><\/table><\/figure>\n","protected":false},"excerpt":{"rendered":"<p>TOCILIZUMAB VS CORTICOSTEROIDS FOR RHEUMATOLOGIC-IRAE A PHASE II RANDOMIZED OPEN LABEL STUDY CITAR trial information : Checkpoint Inhibitor Treatment of ARthritis Title : CITAR &#8211; Comparison of the efficacy and safety of early use of IL-6R blockade with tocilizumab in combination with short-term glucocorticoids versus glucocorticoids alone for the treatment of arthritis induced by cancer [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":25,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-3538","page","type-page","status-publish","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>CITAR trial : Checkpoint Inhibitor Treatment of ARthritis - FHU CARE\u00b2<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/fhucare.com\/fr\/clinical-trials\/citar\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"CITAR trial : Checkpoint Inhibitor Treatment of ARthritis - FHU CARE\u00b2\" \/>\n<meta property=\"og:description\" content=\"TOCILIZUMAB VS CORTICOSTEROIDS FOR RHEUMATOLOGIC-IRAE A PHASE II RANDOMIZED OPEN LABEL STUDY CITAR trial information : Checkpoint Inhibitor Treatment of ARthritis Title : CITAR &#8211; Comparison of the efficacy and safety of early use of IL-6R blockade with tocilizumab in combination with short-term glucocorticoids versus glucocorticoids alone for the treatment of arthritis induced by cancer [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/fhucare.com\/fr\/clinical-trials\/citar\/\" \/>\n<meta property=\"og:site_name\" content=\"FHU CARE\u00b2\" \/>\n<meta property=\"article:modified_time\" content=\"2026-03-05T13:26:45+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/fhucare.com\/wp-content\/uploads\/2026\/01\/Logo_CITAR.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"400\" \/>\n\t<meta property=\"og:image:height\" content=\"186\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data1\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/fhucare.com\\\/fr\\\/clinical-trials\\\/citar\\\/\",\"url\":\"https:\\\/\\\/fhucare.com\\\/fr\\\/clinical-trials\\\/citar\\\/\",\"name\":\"CITAR trial : Checkpoint Inhibitor Treatment of ARthritis - FHU CARE\u00b2\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/fhucare.com\\\/fr\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/fhucare.com\\\/fr\\\/clinical-trials\\\/citar\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/fhucare.com\\\/fr\\\/clinical-trials\\\/citar\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/fhucare.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/Logo_CITAR.webp\",\"datePublished\":\"2026-01-19T11:59:18+00:00\",\"dateModified\":\"2026-03-05T13:26:45+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/fhucare.com\\\/fr\\\/clinical-trials\\\/citar\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/fhucare.com\\\/fr\\\/clinical-trials\\\/citar\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/fhucare.com\\\/fr\\\/clinical-trials\\\/citar\\\/#primaryimage\",\"url\":\"https:\\\/\\\/fhucare.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/Logo_CITAR.webp\",\"contentUrl\":\"https:\\\/\\\/fhucare.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/Logo_CITAR.webp\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/fhucare.com\\\/fr\\\/clinical-trials\\\/citar\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\\\/\\\/fhucare.com\\\/fr\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Clinical trials\",\"item\":\"https:\\\/\\\/fhucare.com\\\/fr\\\/clinical-trials\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"CITAR trial : Checkpoint Inhibitor Treatment of ARthritis\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/fhucare.com\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/fhucare.com\\\/fr\\\/\",\"name\":\"FHU CARE\u00b2\",\"description\":\"Innovations in Autoimmunity, Cancer &amp; Immunotherapies\",\"publisher\":{\"@id\":\"https:\\\/\\\/fhucare.com\\\/fr\\\/#organization\"},\"alternateName\":\"CARE2\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/fhucare.com\\\/fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/fhucare.com\\\/fr\\\/#organization\",\"name\":\"FHU CARE\u00b2\",\"alternateName\":\"CARE2\",\"url\":\"https:\\\/\\\/fhucare.com\\\/fr\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/fhucare.com\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/fhucare.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/CARE2-COULEUR.svg\",\"contentUrl\":\"https:\\\/\\\/fhucare.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/CARE2-COULEUR.svg\",\"caption\":\"FHU CARE\u00b2\"},\"image\":{\"@id\":\"https:\\\/\\\/fhucare.com\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.linkedin.com\\\/in\\\/fhucare\\\/\",\"https:\\\/\\\/www.youtube.com\\\/@fhucare\\\/\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"CITAR trial : Checkpoint Inhibitor Treatment of ARthritis - FHU CARE\u00b2","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/fhucare.com\/fr\/clinical-trials\/citar\/","og_locale":"fr_FR","og_type":"article","og_title":"CITAR trial : Checkpoint Inhibitor Treatment of ARthritis - FHU CARE\u00b2","og_description":"TOCILIZUMAB VS CORTICOSTEROIDS FOR RHEUMATOLOGIC-IRAE A PHASE II RANDOMIZED OPEN LABEL STUDY CITAR trial information : Checkpoint Inhibitor Treatment of ARthritis Title : CITAR &#8211; Comparison of the efficacy and safety of early use of IL-6R blockade with tocilizumab in combination with short-term glucocorticoids versus glucocorticoids alone for the treatment of arthritis induced by cancer [&hellip;]","og_url":"https:\/\/fhucare.com\/fr\/clinical-trials\/citar\/","og_site_name":"FHU CARE\u00b2","article_modified_time":"2026-03-05T13:26:45+00:00","og_image":[{"width":400,"height":186,"url":"https:\/\/fhucare.com\/wp-content\/uploads\/2026\/01\/Logo_CITAR.webp","type":"image\/webp"}],"twitter_card":"summary_large_image","twitter_misc":{"Dur\u00e9e de lecture estim\u00e9e":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/fhucare.com\/fr\/clinical-trials\/citar\/","url":"https:\/\/fhucare.com\/fr\/clinical-trials\/citar\/","name":"CITAR trial : Checkpoint Inhibitor Treatment of ARthritis - FHU CARE\u00b2","isPartOf":{"@id":"https:\/\/fhucare.com\/fr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/fhucare.com\/fr\/clinical-trials\/citar\/#primaryimage"},"image":{"@id":"https:\/\/fhucare.com\/fr\/clinical-trials\/citar\/#primaryimage"},"thumbnailUrl":"https:\/\/fhucare.com\/wp-content\/uploads\/2026\/01\/Logo_CITAR.webp","datePublished":"2026-01-19T11:59:18+00:00","dateModified":"2026-03-05T13:26:45+00:00","breadcrumb":{"@id":"https:\/\/fhucare.com\/fr\/clinical-trials\/citar\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/fhucare.com\/fr\/clinical-trials\/citar\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/fhucare.com\/fr\/clinical-trials\/citar\/#primaryimage","url":"https:\/\/fhucare.com\/wp-content\/uploads\/2026\/01\/Logo_CITAR.webp","contentUrl":"https:\/\/fhucare.com\/wp-content\/uploads\/2026\/01\/Logo_CITAR.webp"},{"@type":"BreadcrumbList","@id":"https:\/\/fhucare.com\/fr\/clinical-trials\/citar\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/fhucare.com\/fr\/"},{"@type":"ListItem","position":2,"name":"Clinical trials","item":"https:\/\/fhucare.com\/fr\/clinical-trials\/"},{"@type":"ListItem","position":3,"name":"CITAR trial : Checkpoint Inhibitor Treatment of ARthritis"}]},{"@type":"WebSite","@id":"https:\/\/fhucare.com\/fr\/#website","url":"https:\/\/fhucare.com\/fr\/","name":"FHU CARE\u00b2","description":"Innovations in Autoimmunity, Cancer &amp; Immunotherapies","publisher":{"@id":"https:\/\/fhucare.com\/fr\/#organization"},"alternateName":"CARE2","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/fhucare.com\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/fhucare.com\/fr\/#organization","name":"FHU CARE\u00b2","alternateName":"CARE2","url":"https:\/\/fhucare.com\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/fhucare.com\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/fhucare.com\/wp-content\/uploads\/2025\/11\/CARE2-COULEUR.svg","contentUrl":"https:\/\/fhucare.com\/wp-content\/uploads\/2025\/11\/CARE2-COULEUR.svg","caption":"FHU CARE\u00b2"},"image":{"@id":"https:\/\/fhucare.com\/fr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.linkedin.com\/in\/fhucare\/","https:\/\/www.youtube.com\/@fhucare\/"]}]}},"_links":{"self":[{"href":"https:\/\/fhucare.com\/fr\/wp-json\/wp\/v2\/pages\/3538","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/fhucare.com\/fr\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/fhucare.com\/fr\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/fhucare.com\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/fhucare.com\/fr\/wp-json\/wp\/v2\/comments?post=3538"}],"version-history":[{"count":8,"href":"https:\/\/fhucare.com\/fr\/wp-json\/wp\/v2\/pages\/3538\/revisions"}],"predecessor-version":[{"id":4695,"href":"https:\/\/fhucare.com\/fr\/wp-json\/wp\/v2\/pages\/3538\/revisions\/4695"}],"up":[{"embeddable":true,"href":"https:\/\/fhucare.com\/fr\/wp-json\/wp\/v2\/pages\/25"}],"wp:attachment":[{"href":"https:\/\/fhucare.com\/fr\/wp-json\/wp\/v2\/media?parent=3538"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}